<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Respir Res</journal-id><journal-title>Respiratory Research</journal-title><issn pub-type="ppub">1465-9921</issn><issn pub-type="epub">1465-993X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1465-9921-7-58</article-id><article-id pub-id-type="pmid">16597326</article-id><article-id pub-id-type="doi">10.1186/1465-9921-7-58</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Overexpression of endothelial nitric oxide synthase suppresses features of allergic asthma in mice</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Broeke</surname><given-names>Robert Ten</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>rtenbroeke@yahoo.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>De Crom</surname><given-names>Rini</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>r.decrom@erasmusmc.nl</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Van Haperen</surname><given-names>Rien</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>r.vanhaperen@erasmusmc.nl</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Verweij</surname><given-names>Vivienne</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>v.verweij@pharm.uu.nl</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Leusink-Muis</surname><given-names>Thea</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>a.muis@pharm.uu.nl</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Van Ark</surname><given-names>Ingrid</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>i.vanark@pharm.uu.nl</email></contrib><contrib id="A7" contrib-type="author"><name><surname>De Clerck</surname><given-names>Fred</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I5">5</xref><email>f.declerck@pharm.uu.nl</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Nijkamp</surname><given-names>Frans P</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>f.p.nijkamp@pharm.uu.nl</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Folkerts</surname><given-names>Gert</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>g.folkerts@pharm.uu.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Pharmacology and Pathophysiology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80.082, 3508 TB Utrecht, The Netherlands</aff><aff id="I2"><label>2</label>St Antonius Hospital, Nieuwegein, The Netherlands</aff><aff id="I3"><label>3</label>Department of Cell Biology &#x00026; Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands</aff><aff id="I4"><label>4</label>Department of Vascular Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands</aff><aff id="I5"><label>5</label>Janssen Research Foundation, Beerse, Belgium</aff><pub-date pub-type="ppub"><year>2006</year></pub-date><pub-date pub-type="epub"><day>5</day><month>4</month><year>2006</year></pub-date><volume>7</volume><issue>1</issue><fpage>58</fpage><lpage>58</lpage><ext-link ext-link-type="uri" xlink:href="http://respiratory-research.com/content/7/1/58"/><history><date date-type="received"><day>3</day><month>1</month><year>2006</year></date><date date-type="accepted"><day>5</day><month>4</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Broeke et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Broeke et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Broeke Ten Robert rtenbroeke@yahoo.com </dc:author><dc:title> Overexpression of endothelial nitric oxide synthase suppresses features of allergic asthma in mice </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>Respiratory Research 7(1): 58-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1465-9921(2006)7:1&#x0003c;58&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1465-9921</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Asthma is associated with airway hyperresponsiveness and enhanced T-cell number/activity on one hand and increased levels of exhaled nitric oxide (NO) with expression of inducible NO synthase (iNOS) on the other hand. These findings are in paradox, as NO also relaxes airway smooth muscle and has immunosuppressive properties. The exact role of the endothelial NOS (eNOS) isoform in asthma is still unknown. We hypothezised that a delicate regulation in the production of NO and its bioactive forms by eNOS might be the key to the pathogenesis of asthma.</p></sec><sec sec-type="methods"><title>Methods</title><p>The contribution of eNOS on the development of asthmatic features was examined. We used transgenic mice that overexpress eNOS and measured characteristic features of allergic asthma after sensitisation and challenge of these mice with the allergen ovalbumin.</p></sec><sec><title>Results</title><p>eNOS overexpression resulted in both increased eNOS activity and NO production in the lungs. Isolated thoracic lymph nodes cells from eNOS overexpressing mice that have been sensitized and challenged with ovalbumin produced significantly less of the cytokines IFN-&#x003b3;, IL-5 and IL-10. No difference in serum IgE levels could be found. Further, there was a 50% reduction in the number of lymphocytes and eosinophils in the lung lavage fluid of these animals. Finally, airway hyperresponsiveness to methacholine was abolished in eNOS overexpressing mice.</p></sec><sec><title>Conclusion</title><p>These findings demonstrate that eNOS overexpression attenuates both airway inflammation and airway hyperresponsiveness in a model of allergic asthma. We suggest that a delicate balance in the production of bioactive forms of NO derived from eNOS might be essential in the pathophysiology of asthma.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Asthma is a chronic inflammatory disease of the airways characterized by airway obstruction, epithelial damage and airway hyperresponsiveness [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. The increased airway responsiveness is believed to be the result of airway inflammation as well as epithelial damage [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. There is increasing evidence that activated T lymphocytes modulate the pathogenesis of asthma [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Specifically, increased numbers of CD4<sup>+ </sup>T cells (Th2) have been found in the bronchial mucosa of asthmatic patients, with the consequent elevated levels of interleukin-5 (IL-5) and IL-10 [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. Moreover, interferon-&#x003b3; (IFN-&#x003b3;) secreting T cells (Th1) were increased in bronchoalveolar lavage (BAL) fluid of asthmatic patients [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>] and it has been reported that these T cells can induce airway inflammation with neutrophilic inflammation [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. Therefore, both Th1 and Th2 cells are important in airway inflammation and asthma [<xref ref-type="bibr" rid="B15">15</xref>]. In addition, inflammatory cells like eosinophils, macrophages and neutrophils are capable of releasing cytokines, proteases, reactive oxygen species and lipid mediators that contribute to the pathogenesis of asthma and the development of airway hyperresponsiveness [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B18">18</xref>].</p><p>Nitric oxide (NO) regulates many physiological processes [<xref ref-type="bibr" rid="B19">19</xref>]. NO itself has a short half-life (1&#x02013;5 s) because of its reactivity with various biological compounds. On one hand NO might react with reactive oxygen species resulting in nitrosative stress; on the other hand it might modificate cysteine sulphurs to form S-nitrosothiols [<xref ref-type="bibr" rid="B20">20</xref>], of which S-nitrosoglutathione represents a major source of bronchodilatory NO activity [<xref ref-type="bibr" rid="B21">21</xref>] NO is synthesized from L-arginine by the enzyme NO synthase (NOS), which exists in three distinct isoforms: constitutive neural NOS (nNOS), inducible NOS (iNOS) and constitutive endothelial or epithelial NOS (eNOS). The isoforms are products of distinct genes located on different human chromosomes, each with a characteristic pattern of tissue-specific expression. NO produced by cNOS acts as a signalling molecule in several processes, including regulation of vascular and airway smooth muscle tone [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. The role of this calcium-dependent isoform in the airways has been previously investigated. Incubation of NOS inhibitors on the mucosal side of the guinea pig trachea induced an increased contractile response to histamine and cholinergic agonists [<xref ref-type="bibr" rid="B23">23</xref>]. Moreover, a NO deficiency in the airways contributes to the development of airway hyperresponsiveness in animal models for asthma, i.e. guinea pigs with a viral respiratory tract infection [<xref ref-type="bibr" rid="B24">24</xref>] and ovalbumin-sensitized and challenged guinea pigs [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. Inhalation of exogenous NO causes bronchodilation in asthmatic patients [<xref ref-type="bibr" rid="B27">27</xref>] and inhibition of NO production by NO synthase inhibitors increases airway responsiveness in patients with mild asthma [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. The calcium-independent iNOS is induced in a wide variety of cell types by several cytokines. NO production by iNOS is several times higher than by cNOS [<xref ref-type="bibr" rid="B30">30</xref>]. In the airway epithelium of human asthmatics, increased expression of iNOS has been found [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>] and high levels of NO produced by this NOS isoform is thought to reflect the increased exhaled NO levels found in asthmatic patients [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. Therefore, it has been suggested that NO produced by iNOS is a marker of inflammation.</p><p>Several studies have shown the importance of the different NOS isoforms in asthma, either by using selective NOS inhibitors or by using mouse strains with deletions in one of the NOS genes. However, no studies have been performed to investigate the effects of overexpression of one of the NOS isoforms on the development of asthmatic features. Furthermore, although the importance of iNOS in asthma is well established [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B34">34</xref>], the precise role of eNOS is still unknown. Interestingly, recent studies suggest that eNOS gene polymorphisms are implicated in asthma [<xref ref-type="bibr" rid="B35">35</xref>-<xref ref-type="bibr" rid="B38">38</xref>]. In the presence of epithelial dysfunction, these polymorphisms may have clinical significance [<xref ref-type="bibr" rid="B39">39</xref>].</p><p>In the present study, we examined the contribution of eNOS on the development of asthmatic features. We used transgenic mice that overexpress eNOS and measured characteristic features of allergic asthma after sensitisation and challenge of these mice with the allergen ovalbumin. We found that eNOS overexpression prevents the development of airway hyperresponsiveness. Furthermore, there was a reduction in the number of inflammatory cells, especially eosinophils, in the lungs and an attenuated production of cytokines by lymph node cells in these animals. We conclude that eNOS overexpression result in attenuation of both airway hyperresponsiveness and airway inflammation.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Generation of eNOS transgenic mice</title><p>A genomic clone has been isolated from a home-made cosmid library [<xref ref-type="bibr" rid="B40">40</xref>]. It comprises the complete, unmodified gene encoding endothelial NO synthase (eNOS, NOS3) plus its natural flanking sequences. These consist of ~ 6 kb of the 5' sequence, including the natural promotor, and ~ 3 kb of the 3' sequence. Vector sequences were removed by restriction endonuclease digestion and DNA was dissolved in micro-injection buffer (10 mmol/L Tris-HCl, pH 7.5; 0.1 mmol/L EDTA) at a concentration of 2 &#x003bc;g/ml. The DNA was micro-injected into fertilized oocytes from FVB mice. These oocytes were transferred into the oviducts of pseudopregnant foster females. Mice used in the present study were backcrossed for at least 5 generations onto a C57BL/6 background (&#x0003e;96% C57BL/6), the controls (WT) for the eNOS overexpressing mice (eNOS). The mice were housed in macrolon cages and provided with food and water ad libitum. All animal experiments were performed in compliance with the Guidelines of the Ethical Committee on the Use of Laboratory Animals of The University Utrecht and Erasmus University Rotterdam.</p></sec><sec><title>eNOS activity measurements</title><p>eNOS activity was measured in lung tissue by the L-arginine to L-citrulline conversion assay using a nitric oxide synthase assay kit (Calbiochem, La Jolla, CA, USA; cat. no. 482700) according to the manufacturer's instructions.</p></sec><sec><title>Western blot analysis of eNOS</title><p>Lung tissue isolated from control or eNOS overexpressing mice were homogenized in 1 ml of 50 mM Tris-HCl buffer, pH 7.8, containing 150 mM NaCl, 1 mM EDTA, 1 mM sodium vanadate, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride (PMSF). The samples were transferred to eppendorf tubes and centrifuged at high speed in a microcentrifuge for 10 minutes at 4&#x000b0;C to remove insoluble material. Protein content was determined using the method of Bradford [<xref ref-type="bibr" rid="B41">41</xref>] with BSA as standard. Equal amounts of protein were added to a 0.1 M Tris buffer containing 50 &#x003bc;M dithiothreitol, 0.01% bromophenol blue, 1% sodium dodecyl sulfate (SDS) and 10% glycerol and boiled for 5 minutes. Proteins (30 &#x003bc;g/lane) were electrophoresed under reducing, denaturing conditions in 7.5% SDS polyacrylamide gel, transferred to nitrocellulose paper and probed with an antibody against humans eNOS (Santa Cruz Biotechnology, Inc., Santa Cruz, California, USA) or with an antibody against the phosphorylated site of eNOS (P-eNOS, Cell Signaling Technology, Beverly, MA, USA). Antibody binding was detected using an amplified alkaline phosphatase immuno blot kit (Biorad Laboratories, Hercules, California, USA) according to the manufacturer's recommendation.</p></sec><sec><title>Sensitization and challenge</title><p>All mice were sensitized to ovalbumin (OVA; chicken egg albumin, grade V, Sigma, St. Louis, MO, USA). Active sensitization was performed by 2 intraperitoneal injections of 0.1 ml alum-precipitated antigen, comprising 10 &#x003bc;g OVA absorbed onto 2.25 mg alum (AlumImject; Pierce, Rockford, IL, USA) on day 0 and 14. Four weeks after the last injection, the mice were exposed either to an OVA (10 mg/ml in pyrogen-free saline, OVA group) or control solution (saline, SAL group) aerosol challenge for 20 minutes once daily on day 42, 45 and 48. The aerosol was performed in a plexiglass exposure chamber (5 L) coupled to a Pari LC Star nebulizer (PARI Respiratory Equipment, Richmond, VA, USA; particle size 2.5&#x02013;3.1 &#x003bc;m) driven by compressed air at a flow rate of 6 L/min. Aerosol was given in groups composed of 6 animals.</p></sec><sec><title>Measurement of airway responsiveness in vivo</title><p>Airway responsiveness was measured in conscious, unrestrained mice 24 hours after the last aerosol exposure using barometric whole-body plethysmography by recording respiratory pressure curves (Buxco; EMKA Technologies, Paris, France) in response to inhaled methacholine (acetyl-&#x003b2;-methyl-choline chloride, Sigma). Airway responsiveness was expressed in enhanced pause (Penh), which is a measure of bronchoconstriction, as described in detail previously [<xref ref-type="bibr" rid="B42">42</xref>]. Briefly, mice were placed in a whole-body chamber, and basal readings were obtained and averaged for 3 min. Aerosolized saline, followed by increasing doubling concentrations (1.56 &#x02013; 25 mg/ml saline) of methacholine, were nebulized for 3 min, and readings were taken and averaged for 3 min after each nebulization.</p></sec><sec><title>Analysis of cellular composition of bronchoalveolar lavage (BAL) fluid</title><p>Following airway responsiveness measurements, mice received a lethal dose of pentobarbitone sodium (Euthesate<sup>&#x000ae; </sup>0.6 mg/kg body weight, intraperitoneally). The trachea was trimmed free of connective tissue and a small incision was made to insert a cannula in the trachea. Via this cannula, the lungs were filled with 1 ml aliquots of pyrogen free saline (37&#x000b0;C) supplemented with aprotinin (2 &#x003bc;g/ml, Sigma). Fluid was collected in plastic tubes on ice. This procedure was repeated 3 times with aliquots of pyrogen free saline and fluid was collected in a separate plastic tube on ice and cell suspensions recovered from each animal were pooled. BAL cells were centrifuged (400 &#x000d7; g, 4&#x000b0;C, 5 min) and supernatant from 1 ml aliquots were collected and stored (-30&#x000b0;C) until cytokines and NO were measured by ELISA and NO analyzer. The pellets from the first ml and 3 ml aliquots were pooled and resuspended in 150 &#x003bc;l PBS. The total number of cells in the BAL fluid was determined using a B&#x000fc;rker-T&#x000fc;rk bright-line counting chamber (Karl Hecht Assistant KG, Sondheim/Rohm, Germany). For differential BAL fluid cell counts, cytospin preparations were made and stained with Diff-Quik (Dade AG, D&#x000fc;dingen, Switzerland). Per cytospin, 200 cells were counted and differentiated into alveolar macrophages, eosinophils, lymphocytes and neutrophils by light microscopical observation under oil immersion.</p></sec><sec><title>Serum levels of total IgE</title><p>Blood samples were obtained from the mice via a cardiac puncture, left at room temperature for two hours and subsequently centrifuged for 10 min at 20,000 &#x000d7; g. Serum was collected and samples were kept at -20&#x000b0;C until analysis. Total IgE was measured using an ELISA method. Briefly, microtiter plates (Nunc A/S, Roskilde, Denmark) were coated overnight at 4&#x000b0;C with 2 &#x003bc;g/ml rat anti-mouse IgE (clone EM95) diluted in phosphate-buffered saline (PBS). The next day, the ELISA was performed at room temperature. After blocking with ELISA buffer (PBS containing 0.5% bovine serum albumin (Sigma), 2 mM EDTA, 136.9 mM NaCl, 50 mM Tris, 0.05% Tween-20 (Merck, Whitehouse Station, NJ, USA) pH 7.2) for 1 hour, serum samples diluted in ELISA buffer, were added for 2 hours. Thereafter, plates were incubated with 1 &#x003bc;g/ml second biotinylated antibody (Biotin anti-mouse IgE, PharMingen, San Diego, CA, USA) diluted in ELISA buffer for 1.5 hours. After washing, streptavidin-peroxidase (0.1 &#x003bc;g/ml, CLB, Amsterdam, The Netherlands) was added and incubation was performed for 1 hour. Color development was performed with o-phenylenediamine-dichloride substrate (0.4 mg/ml; Sigma) and 0.04% H<sub>2</sub>O<sub>2 </sub>in PBS and stopped by adding 4 M H<sub>2</sub>SO<sub>4</sub>. The optical density was read at 492 nm, using a Benchmark microplate reader (Bio-Rad Laboratories, Hercules, CA, USA).</p></sec><sec><title>Determination of cytokine production by OVA-restimulated thoracic lymph nodes cells in vitro</title><p>Cytokine production by antigen-stimulated T cells derived from thoracic lymph nodes (TLN) was determined as described previously [<xref ref-type="bibr" rid="B43">43</xref>]. Briefly, TLN draining the lungs were removed, transferred to cold sterile PBS and filtered through a 70- &#x003bc;m nylon cell strainer (Becton Dickinson Labware, Franklin Lakes, NJ) with 10 ml RPMI 1640 to obtain a single-cell suspension. The lymph node cells were washed and resuspended in culture medium (RPMI 1640 containing 10% FCS, 1% glutamax I, and gentamicin (all from Life Technologies, Gaithersburg, MD, USA) and 50 mM -mercaptoethanol (Sigma). Cells were cultured in flat bottom 96-well plates (Greiner Bio-One GmbH, Kremsmuenster, Austria) at a concentration of 1 &#x000d7; 10<sup>6 </sup>cells per ml in a volume of 200 &#x003bc;l. The cells were cultured for 5 days (37&#x000b0;C with 5% CO<sub>2 </sub>in humidified air) with culture medium or OVA (10 &#x003bc;g/ml). Each in vitro stimulation was performed in triplicate. After 5 days of culture, the supernatant was harvested, pooled per stimulation, and stored at -20&#x000b0;C until cytokine levels were determined by ELISA. The IFN-&#x003b3;, IL-5 and IL-10 ELISAs were performed according to the manufacturer's instructions (PharMingen, San Diego, CA, USA).</p></sec><sec><title>Determination of cytokine levels in BAL fluid</title><p>Cytokine levels were determined in supernatant of the first ml of the lavage fluid by ELISA (see above). IFN-&#x003b3; and IL-10 levels in BAL fluid were below detection limit.</p></sec><sec><title>Measurement of NO in BAL fluid</title><p>NO levels were determined in the BAL fluid. Therefore, the first ml of the lavage fluid was centrifuged and the supernatant was kept at -20&#x000b0;C until analysis. The remaining pellet was resuspended in the recovered lavage fluid and used to determine total and differential cell numbers (see above). Both nitrite, nitrate and S-nitrosothiol levels (NO<sub>x</sub>) in BAL fluid were determined as stable and representative breakdown products of NO [<xref ref-type="bibr" rid="B44">44</xref>]. Therefore, samples of 25 &#x003bc;l of BAL fluid were injected into a gas stripping apparatus containing 2 ml of a 1% solution of vanadium (III) chloride in hydrochloric acid at 90&#x000b0;C which was connected to a Sievers 280i NO analyser (Boulder, CO, USA). NO was measured according to the instructions of the manufacturer (Sievers Nitric Oxide Analyzer NO A280, Operational Service Manual, Boulder, CO, USA; Sievers Instruments I 1996) [<xref ref-type="bibr" rid="B45">45</xref>]. The sensitivity of the NO analyser is &#x0003c; 10 pmol/ml, with a linearity of 4 orders of magnitude. Calibrations were made according to the manufacturer's instructions with standard solutions of sodium nitrate and sodium nitrate (Sigma), respectively [<xref ref-type="bibr" rid="B46">46</xref>].</p></sec><sec><title>Statistical analysis</title><p>All data are expressed as mean &#x000b1; SEM. Differences in eNOS activity, total NO levels in BAL fluid, total and differential cell numbers in BAL fluid, cytokine production by thoracic lymph nodes and IL-5 levels in BAL fluid were tested using the Student's <italic>t</italic>-test (unpaired). Differences between groups after aerosolized methacholine were tested by a general linear model of repeated measurements followed by post-hoc comparison between groups. Data were log transformed before analysis to equalize variances in all groups. Also, the Student's <italic>t</italic>-test (unpaired) was used to determine statistical differences between groups at 25 mg/ml methacholine concentration. All p-values &#x0003c;0.05 were considered to reflect a statistically significant difference.</p></sec></sec><sec><title>Results</title><sec><title>Increased eNOS overexpression and eNOS activity in lungs of eNOS overexpressing mice</title><p>The presence of eNOS protein in lung tissue was detected by immunoblotting using two different antibodies. First, using an antibody against human eNOS (&#x003b1;-eNOS), a faint band was observed in lung tissue from WT animals, whereas a much more prominent band could be detected with lung tissue derived from eNOS mice (Fig <xref ref-type="fig" rid="F1">1A</xref>). Secondly, since the enzymatic activity of eNOS is tightly regulated by different mechanisms, such as the phosphorylation on Ser1179 by the serine/threonine protein kinase Akt [<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B48">48</xref>], we also used an antibody against phosphorylated eNOS (&#x003b1;-P-eNOS). As shown in figure <xref ref-type="fig" rid="F1">1</xref>, endogenous mouse P-eNOS was not detectable in the WT mice, whereas P-eNOS was present in lungs from eNOS mice.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Immunoblotting of lung tissue from WT and eNOS mice. Increased expression of both eNOS (&#x003b1;-eNOS) and phosphorylated eNOS (&#x003b1;-P-eNOS) was found in eNOS mice compared to WT mice. Experiments have been performed at least three times in which similar results were obtained.</p></caption><graphic xlink:href="1465-9921-7-58-1"/></fig><p>We also measured eNOS activity in lungs from WT mice and eNOS overexpressing mice using the L-arginine to L-citrulline conversion assay. The eNOS mice showed a 25-fold increased activity compared to WT mice (Fig <xref ref-type="fig" rid="F2">2A</xref>). Furthermore, eNOS mice produce more NO in the lungs, since nitrite and nitrate (NO<sub>x</sub>) levels in BAL fluid were increased by 90% in eNOS mice (SAL/eNOS) compared to WT mice (SAL/WT, Fig <xref ref-type="fig" rid="F2">2B</xref>). From these data we conclude that eNOS is indeed overexpressed in eNOS mice and that eNOS activity is increased in these mice.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>(<bold>A</bold>) eNOS activity in lung homogenates from WT (white bars) and eNOS (hatched bars) mice measured by using the arginine to citrulline conversion assay and (<bold>B</bold>) NO<sub>x </sub>levels measured in BAL fluid of WT mice (white bars) and eNOS mice (hatched bars). Increased eNOS activity was observed in eNOS mice compared to WT mice. NO<sub>x </sub>levels were higher in eNOS mice compared to WT mice. eNOS activity is expressed as mean &#x000b1; SEM arbitrary units, n = 6. NO<sub>x </sub>data are presented as mean &#x000b1; SEM, n = 6. <sup>### </sup>p &#x0003c; 0.001 compared to WT mice.</p></caption><graphic xlink:href="1465-9921-7-58-2"/></fig></sec><sec><title>eNOS is localized in endothelium</title><p>The localization of eNOS expressed by the transgenic mice was evaluated by immunohistochemistry studies in lung sections. While the alveolar septa of control mice were only faintly stained, these show a strong signal in transgenic mice (Fig <xref ref-type="fig" rid="F3">3A</xref> and <xref ref-type="fig" rid="F3">3B</xref>, respectively). The staining appeared to be present in the interior parts of the alveolar septa, which is clearly visible at a higher magnification (Fig <xref ref-type="fig" rid="F3">3C</xref>), in which immuno-positive capillaries in the septa can be discriminated while the type I cells that line the alveolar surfaces are not stained. Bronchioles are not stained (Fig <xref ref-type="fig" rid="F3">3D</xref>).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>Immunohistochemistry of sections from lung tissue with antibodies directed against human eNOS. <bold>A</bold>) Control mice: Only a faint background staining is present. <bold>B</bold>) eNOS transgenic mice: eNOS is localized in the alveolar septa in lungs. <bold>C</bold>) eNOS transgenic mice: eNOS is present within the septa. Arrowheads point at alveolar capillaries. No signal is seen in the type I cells lining the alveoli (double arrowheads). <bold>D</bold>) eNOS transgenic mice: No signal is seen in the cells from the bronchiole (Br), while the endothelial cells from the small vessel accompanying the bronchiole show staining (arrow). Original magnifications: 100&#x000d7; (A, B, D) and 630&#x000d7; (C). Experiments have been performed at least three times in which similar results were obtained.</p></caption><graphic xlink:href="1465-9921-7-58-3"/></fig></sec><sec><title>eNOS overexpression suppresses the influx of inflammatory cells into the lungs</title><p>To study the effects of eNOS overexpression on the influx of inflammatory cells into the lungs after OVA challenge, total and differential cell numbers in the BAL fluid 24 hours after OVA challenge were determined. Total cell numbers of SAL/WT and SAL/eNOS mice were 13.4 &#x000b1; 1.2 &#x000d7; 10<sup>4 </sup>and 25.3 &#x000b1; 4.7 &#x000d7; 10<sup>4</sup>, respectively (p &#x0003c; 0.05). The number of alveolar macrophages was more than two times higher in SAL/eNOS mice compared to SAL/WT mice (p &#x0003c; 0.01, Fig <xref ref-type="fig" rid="F4">4B</xref>). Also a small, but not significant (NS, p = 0.09) increase in the number of lymphocytes could be observed in SAL/eNOS mice compared to SAL/WT mice (Fig <xref ref-type="fig" rid="F4">4C</xref>). Eosinophils (Fig <xref ref-type="fig" rid="F4">4D</xref>) and neutrophils (data not shown) were not present in BAL fluid of both SAL/WT and SAL/eNOS mice. Aerosol OVA exposure increased the total cell numbers to 695 &#x000b1; 48 &#x000d7; 10<sup>4 </sup>in OVA/WT mice and to 366 &#x000b1; 32 &#x000d7; 10<sup>4 </sup>in OVA/eNOS mice. Therefore, there was a 47% reduction (p &#x0003c; 0.001) in total cell numbers in OVA/eNOS compared to OVA/WT mice (Fig <xref ref-type="fig" rid="F4">4A</xref>). The increase in total cell numbers after OVA challenge was mainly due to an increase in the number of eosinophils (80% of total cell population in OVA/WT mice). In OVA/eNOS mice, there was a 46% reduction in the number of eosinophils compared to OVA/WT mice (p &#x0003c; 0.001, Fig <xref ref-type="fig" rid="F4">4D</xref>). Furthermore, eNOS overexpression reduced the increase in the number of lymphocytes (54%, p &#x0003c; 0.05, Fig <xref ref-type="fig" rid="F4">4C</xref>) after OVA challenge. However, no difference in the number of macrophages (Fig <xref ref-type="fig" rid="F4">4B</xref>) and neutrophils (data not shown) could be found in OVA/eNOS mice compared to OVA/WT mice. From these results we conclude that eNOS overexpression reduces the influx of inflammatory cells, predominantly eosinophils, into the lungs after OVA challenge.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p>Cell numbers in BAL fluid obtained 24 hours after challenge from SAL/WT mice (white bars), SAL/eNOS mice (hatched bars), OVA/WT mice (black bars) and OVA/eNOS mice (grey bars). <bold>A</bold>) total cell numbers in BAL fluid. Total cell numbers are increased in OVA/WT mice compared to SAL/WT mice. Total cell numbers are decreased by 47% in OVA/eNOS mice compared to OVA/WT mice. <bold>B</bold>) number of alveolar macrophages in BAL fluid. The number of macrophages is increased in SAL/eNOS mice compared to SAL/WT mice. Numbers of macrophages were 4 times increased in OVA/WT mice compared to SAL/WT mice. No difference in macrophages was observed between OVA/eNOS and OVA/WT mice. <bold>C</bold>) number of lymphocytes in BAL fluid. Hardly any lymphocytes could be detected in SAL/WT and SAL/eNOS mice. A markedly increased number of lymphocytes were found in OVA/WT mice compared to SAL/WT mice. A 54% reduction in lymphocytes was found in OVA/eNOS mice compared to OVA/WT mice (p &#x0003c; 0.05). <bold>D</bold>) number of eosinophils in BAL fluid. No eosinophils were present in the BAL fluid of SAL/WT mice and SAL/eNOS mice (ND = not detectable). A dramatic increase in eosinophils was detected in OVA/WT mice compared to SAL/WT mice. Compared to OVA/WT, there was a 46% reduction in the increase in eosinophils in the BAL fluid in OVA/eNOS mice (p &#x0003c; 0.001). Data are presented as mean &#x000b1; SEM, n = 9. * p &#x0003c; 0.05, ** p &#x0003c; 0.01, <sup>$$ </sup>p &#x0003c; 0.01, *** p &#x0003c; 0.001 compared to SAL/WT mice, <sup># </sup>p &#x0003c; 0.05, <sup>### </sup>p &#x0003c; 0.001 compared to OVA/WT mice.</p></caption><graphic xlink:href="1465-9921-7-58-4"/></fig></sec><sec><title>eNOS overexpression does not affect IgE levels in serum</title><p>eNOS overexpression in SAL challenged mice had no influence on IgE levels in serum (Fig <xref ref-type="fig" rid="F5">5A</xref>). Antigen challenge induced a significant increase in serum levels of total IgE in both WT mice (p &#x0003c; 0.01) and eNOS mice (p &#x0003c; 0.01), compared to SAL challenged mice (Fig <xref ref-type="fig" rid="F5">5A</xref>). No difference in serum IgE levels between OVA/WT and OVA/eNOS mice could be observed (Fig <xref ref-type="fig" rid="F5">5A</xref>). From this we conclude that eNOS overexpression has no effect on IgE levels in serum both after saline and ovalbumin challenge.</p><fig position="float" id="F5"><label>Figure 5</label><caption><p>Ovalbumin-specific IgE levels in serum and different production of cytokines by TLN cells after OVA restimulation in vitro in SAL/WT mice (white bars), SAL/eNOS mice (hatched bars), OVA/WT mice (black bars) and OVA/eNOS mice (grey bars). <bold>A</bold>) IgE levels in serum 24 hours after challenge. An increase in IgE was observed after OVA challenge. No difference between eNOS and the respective WT mice was detected. <bold>B</bold>) IFN-&#x003b3; production by TLN. No IFN-&#x003b3; was produced by TLN cells obtained from SAL/WT and SAL/eNOS mice. IFN-&#x003b3; production was markedly increased in OVA/WT mice, but only slightly in OVA/eNOS mice. <bold>C</bold>) IL-5 production by TLN cells. Low levels of IL-5 were found in SAL/WT mice, whereas no IL-5 production was found in SAL/eNOS mice. IL-5 levels were markedly increased in OVA/WT mice compared to SAL/WT mice. IL-5 production was decreased by 44% in OVA/eNOS mice compared to OVA/WT mice (p &#x0003c; 0.01). <bold>D</bold>) IL-10 production by TLN cells. Low levels of IL-10 were found in SAL/WT mice, whereas no IL-10 production was found in SAL/eNOS mice. IL-10 levels were increased in OVA/WT mice compared to SAL/WT mice. IL-10 production was decreased by 51% in OVA/eNOS mice compared to OVA/WT mice (p &#x0003c; 0.01). Data are presented as mean &#x000b1; SEM, n = 6. * p &#x0003c; 0.05, ** p &#x0003c; 0.01, *** p &#x0003c; 0.001, <sup>$$$ </sup>p &#x0003c; 0.001 compared to SAL/WT mice, <sup>## </sup>p &#x0003c; 0.01 compared to OVA/WT mice.</p></caption><graphic xlink:href="1465-9921-7-58-5"/></fig></sec><sec><title>eNOS overexpression suppresses cytokine production by thoracic lymph nodes in vitro</title><p>We next compared the cytokine profiles of TLN cells obtained from WT and eNOS mice. eNOS overexpression in SAL challenged mice had no influence on IFN-&#x003b3; production by TLN cells in vitro (Fig <xref ref-type="fig" rid="F5">5B</xref>). However, IL-5 production (Fig <xref ref-type="fig" rid="F5">5C</xref>) was completely absent in TLN cells obtained from SAL/eNOS mice (0.41 &#x000b1; 0.2 pg/ml) compared to SAL/WT mice (312 &#x000b1; 70 pg/ml). Furthermore, eNOS overexpression significantly (p &#x0003c; 0.001) reduced in vitro production of IL-10 by TLN (4.74 &#x000b1; 1.35 pg/ml in SAL/eNOS mice and 68.9 &#x000b1; 12.1 pg/ml in SAL/WT mice; Fig <xref ref-type="fig" rid="F5">5D</xref>). OVA challenge highly increased IFN-&#x003b3; production in WT mice (p &#x0003c; 0.05) compared to SAL/WT, whereas no significant increase in IFN-&#x003b3; production was observed in cells derived from OVA/eNOS mice compared to SAL/eNOS (Fig <xref ref-type="fig" rid="F5">5B</xref>). Interestingly, IFN-&#x003b3; production was decreased by 90% in OVA/eNOS mice compared to OVA/WT mice. After OVA challenge, an increased production of IL-5 and IL-10 (both p &#x0003c; 0.001) by TLN cells in vitro was found in WT mice (Fig <xref ref-type="fig" rid="F5">5C</xref> + Fig <xref ref-type="fig" rid="F5">5D</xref>). In OVA/eNOS mice, IL-5 and IL-10 production was decreased by 44% and 51%, respectively, compared to OVA/WT mice (both p &#x0003c; 0.01). From this we conclude that eNOS overexpression attenuates IFN-&#x003b3;, IL-5 and IL-10 production by TLN cells in vitro after OVA challenge.</p></sec><sec><title>eNOS overexpression attenuates IL-5 levels in BAL fluid</title><p>Next, we measured IL-5 levels in BAL fluid. eNOS overexpression in SAL challenged mice had no influence on IL-5 levels in BAL fluid (Fig <xref ref-type="fig" rid="F6">6</xref>). IL-5 levels in BAL fluid of OVA/WT mice were significantly increased (p &#x0003c; 0.05) compared to SAL/WT. IL-5 levels in BAL fluid were significantly (p &#x0003c; 0.01) reduced in OVA/eNOS mice compared to OVA/WT mice (Fig <xref ref-type="fig" rid="F6">6</xref>). We conclude that eNOS overexpression reduces IL-5 levels in BAL fluid after OVA challenge.</p><fig position="float" id="F6"><label>Figure 6</label><caption><p>IL-5 levels in BAL fluid in SAL/WT mice (white bars), SAL/eNOS mice (hatched bars), OVA/WT mice (black bars) and OVA/eNOS mice (grey bars). Low levels of IL-5 were found in SAL/WT and SAL/eNOS mice. IL-5 levels were increased in OVA/WT mice compared to SAL/WT mice. IL-5 levels were markedly decreased in OVA/eNOS mice compared to OVA/WT mice. Data are presented as mean &#x000b1; SEM, n = 6. * p &#x0003c; 0.05 compared to SAL/WT mice, <sup>## </sup>p &#x0003c; 0.01 compared to OVA/WT mice.</p></caption><graphic xlink:href="1465-9921-7-58-6"/></fig></sec><sec><title>eNOS overexpression prevents the development of airway hyperresponsiveness</title><p>To investigate the effects of eNOS overexpression on the development of airway hyperresponsiveness, airway responsiveness to methacholine (expressed as Penh values) 24 hours after OVA challenge was measured in unrestrained mice in a Buxco set-up. Basal responsiveness was slightly increased in OVA-challenged mice compared to SAL- challenged mice (0.85 &#x000b1; 0.11 vs 0.71 &#x000b1; 0.06 in WT mice and 0.85 &#x000b1; 0.08 vs 0.65 &#x000b1; 0.04 in eNOS mice). No difference in airway responsiveness to methacholine between SAL/WT mice and SAL/eNOS mice could be observed (Fig <xref ref-type="fig" rid="F7">7</xref>). Airway responsiveness to methacholine was significantly (p &#x0003c; 0.01) increased in OVA/WT mice compared to SAL/WT mice (Fig <xref ref-type="fig" rid="F7">7</xref>). However, no statistically significant difference in airway responsiveness to methacholine could be found between OVA/eNOS mice and SAL/eNOS mice (p = 0.10). In OVA/eNOS mice, there was a 35% reduction in airway responsiveness to 25 mg/ml methacholine compared to OVA/WT mice (p &#x0003c; 0.05, Fig <xref ref-type="fig" rid="F7">7</xref>). Thus, OVA/eNOS mice are less responsive to high concentrations of methacholine compared to OVA/WT mice.</p><fig position="float" id="F7"><label>Figure 7</label><caption><p>Airway responsiveness (expressed as Penh) to aerosolized methacholine was measured in conscious, unrestrained mice 24 hours after challenge. Increased airway responsiveness to methacholine (p &#x0003c; 0.01) was observed in OVA/WT mice (black bar, n = 7) compared to SAL/WT mice (white bar, n = 9). No effect on airway responsiveness was observed in SAL/eNOS mice (hatched bar, n = 7). Airway hyperresponsiveness was abolished in OVA/eNOS mice (grey bar, n = 11) compared to OVA/WT mice (p &#x0003c; 0.05 at 25 mg/ml methacholine). Data are presented as mean &#x000b1; SEM. <sup># </sup>p &#x0003c; 0.05 compared to OVA/WT mice.</p></caption><graphic xlink:href="1465-9921-7-58-7"/></fig></sec></sec><sec><title>Discussion</title><p>NO has been implicated in many physiological and pathophysiological processes and it may play a crucial role in airway functioning both during health and disease [<xref ref-type="bibr" rid="B19">19</xref>]. In healthy situations, NO derived from cNOS seems to be predominant, since low levels of NO produced by cNOS controls airway smooth muscle tone [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B49">49</xref>]. During asthmatic disease however, high levels of NO derived from the iNOS isoform are a major contributor to the inflammatory process seen in asthma [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B34">34</xref>].</p><p>Several studies have shown the importance of the different NOS isoforms in the development of asthmatic features, such as increased airway responsiveness, airway inflammation and increased production of several cytokines. Xiong et al [<xref ref-type="bibr" rid="B34">34</xref>] again stressed the role of the iNOS isoform in the inflammatory process in asthma. In contrast, De Sanctis et al [<xref ref-type="bibr" rid="B50">50</xref>] showed that the iNOS isoform is not important in the development of airway inflammation. Furthermore, Feder et al [<xref ref-type="bibr" rid="B51">51</xref>] showed that a selective iNOS inhibitor had no effect on the influx of eosinophils into the lungs of allergen-challenged mice. Moreover, no increase in pulmonary iNOS was found in sensitized and challenged mice. These findings suggest that the iNOS isoform is not the only factor contributing to airway inflammatory processes. In the present study, we have used eNOS overexpressing mice to explore the effects of this NOS isoform on the development of asthmatic features in a mouse model of allergic asthma. Our results show that eNOS plays a crucial role in both airway hyperresponsiveness and airway inflammation.</p><p>Overexpression of eNOS in mice was confirmed by several ways. First, immunoblot analysis showed eNOS expression in the lungs of overexpressing mice, however, this protein was hardly found in wild type mice. Using the L-arginine to L-citrulline conversion assay, it was demonstrated that eNOS activity was significantly increased in the lungs of overexpressing mice. NO<sub>x </sub>levels were more than doubled in the bronchoalveolar lavage fluid of overexpressing mice and immunohistochemistry indicated an increased expression of eNOS in the lungs. These results indicate that eNOS-derived NO has functional properties in the lungs of these mice [<xref ref-type="bibr" rid="B52">52</xref>].</p><p>NO itself has a very short half-life and reacts rapidly with many different molecules in a biological environment. S-nitrosothiols are important molecules signaling NO bioactivity in the airways. Low levels of S-nitrosothiols are associated with severe asthma [<xref ref-type="bibr" rid="B53">53</xref>], and recently, Que et al. [<xref ref-type="bibr" rid="B21">21</xref>] showed that allergic mice that cannot metabolize S-nitrosothiols are completely protected from airway hyperresponsiveness. Moreover, S-nitrosothiols repressed the action of inhibitory &#x003ba;B kinase, providing a mechanism for the anti-inflammatory properties of NO [<xref ref-type="bibr" rid="B54">54</xref>]. We can speculate that overexpression of eNOS in the airways leads to higher concentrations of NO and the consequent higher levels of S-nitrosothiols in the lungs.</p><p>Airway inflammation is the key factor in the pathogenesis of asthmatic disease [<xref ref-type="bibr" rid="B55">55</xref>]. Besides other inflammatory cells, the eosinophil is thought to be one of the major effector cells in asthma. In the present study we found that eNOS overexpression reduced the influx of eosinophils into the lungs after ovalbumin challenge by 46%. A direct effect of NO on lung eosinophilic influx is doubtful. Although chemical inhibition of NO activity has been shown to suppress pulmonary eosinophilic inflammation in mice [<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B56">56</xref>], in NOS1, 2 and 3 KO mice no difference in the number of lung eosinophils could be observed [<xref ref-type="bibr" rid="B50">50</xref>]. Eosinophil mobilisation and trafficking are largely promoted by the Th2 cytokine IL-5 [<xref ref-type="bibr" rid="B57">57</xref>]. Ablation of the effects of IL-5 has been accomplished with blocking anti-IL-5 antibody, which was accompanied by a reduction in allergen-induced eosinophilia [<xref ref-type="bibr" rid="B58">58</xref>-<xref ref-type="bibr" rid="B60">60</xref>]. We found that IL-5 production by TLN cells in vitro is reduced by 44% in OVA/eNOS mice. Furthermore, IL-5 was almost completely absent in the BAL fluid of these mice. The attenuated IL-5 production might account for the reduced presence of eosinophils in the lungs. Interestingly, IL-5 production by TLN cells was completely absent in SAL/eNOS mice. Therefore, eNOS overexpression might, via inhibition of IL-5 production, attenuate the maturation of eosinophils in the bone marrow [<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B61">61</xref>].</p><p>In the present study, we also found reduced levels of lymphocytes in the BAL fluid of OVA/eNOS mice. Although we did not measure numbers of circulating white blood cells, it has been reported that NO inhibits leukocyte adhesion and migration through the endothelial cell layer [<xref ref-type="bibr" rid="B62">62</xref>]. Since immunohistochemical data showed overexpression of eNOS predominantly in the endothelium, an NO-induced decrease in leukocyte adhesion might, at least partly, offer an explanation for the decreased airway inflammation in this mouse strain. Moreover, NO attenuates T cell proliferation [<xref ref-type="bibr" rid="B63">63</xref>,<xref ref-type="bibr" rid="B64">64</xref>] and, at high levels, NO can induce T cell apoptosis through S-nitrosylation of different target proteins [<xref ref-type="bibr" rid="B65">65</xref>,<xref ref-type="bibr" rid="B66">66</xref>].</p><p>Airway hyperresponsiveness is a well-established characteristic of allergic asthma and is believed to be the result of airway inflammation as well as epithelial damage [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B67">67</xref>]. Interestingly, several studies have shown that eNOS KO mice are hyperresponsive to inhaled bronchoconstrictor agents like methacholine [<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B50">50</xref>]. We show in the present study that the development of airway hyperresponsiveness was completely prevented in OVA/eNOS mice at a high methacholine concentration. It is not unlikely that this is due to the fact that only at high concentration of a bronchoconstricting agent, high levels of NO are necessary to counteract this constriction. This idea is supported by the observation that eNOS overexpression has no effect on basal responsiveness to methacholine.</p><p>A disbalance between Th2 and Th1 lymphocytes seems to be correlated with the development of atopic diseases [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B68">68</xref>]. mRNA expression data in BAL cells from atopic asthmatics showed a predominant Th2 cell like pattern [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>], with the consequent elevation of IL-4 and IL-5 [<xref ref-type="bibr" rid="B69">69</xref>]. Furthermore, Th1 cells are thought to antagonize Th2 cell functions [<xref ref-type="bibr" rid="B7">7</xref>]. Previously, a role for iNOS in the Th1/Th2 balance was proposed, since in iNOS KO mice a suppression of allergic inflammation was found, which was accompanied by an increased IFN-&#x003b3; production by T cells [<xref ref-type="bibr" rid="B34">34</xref>]. However, other studies showed that antigen-specific Th1 cells do not protect or prevent Th2-mediated allergic diseases, but rather may cause acute lung pathology [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B70">70</xref>]. Furthermore, IFN-&#x003b3; levels are elevated in serum [<xref ref-type="bibr" rid="B12">12</xref>] and BAL fluid [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B71">71</xref>] of patients with asthma. Interestingly, treatment with antibodies to IFN-&#x003b3; completely abolished airway hyperresponsiveness, but had no effect on airway eosinophilia [<xref ref-type="bibr" rid="B59">59</xref>]. In contrast, other studies have shown that anti-IL-5 blocks eosinophilic influx into the lungs, although hardly any effect on airway hyperresponsiveness could be observed [<xref ref-type="bibr" rid="B59">59</xref>,<xref ref-type="bibr" rid="B72">72</xref>]. In the present study, we found attenuated levels in OVA/eNOS mice of both the Th1 cytokine IFN-&#x003b3; and the Th2 cytokines IL-5 and IL-10 compared to OVA/WT mice. Therefore, NO derived from eNOS might be involved in the attenuated production of both Th1 and Th2 cytokines, resulting in diminished airway inflammation and, although not causally related [<xref ref-type="bibr" rid="B21">21</xref>], this might reduce the development of airway hyperresponsiveness. Indeed, NO inhibits the secretion of IFN-&#x003b3; by Th1 cells [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B73">73</xref>,<xref ref-type="bibr" rid="B74">74</xref>] and IL-5 and IL-10 by Th2 cells [<xref ref-type="bibr" rid="B75">75</xref>] by affecting several signaling molecules and transcription factors in T cells (recently reviewed in [<xref ref-type="bibr" rid="B76">76</xref>]).</p><p>The role of IL-10 in asthma remains controversial. Some studies found a higher IL-10 expression in subjects with asthma than in control subjects [<xref ref-type="bibr" rid="B77">77</xref>], whereas others found lower IL-10 levels [<xref ref-type="bibr" rid="B78">78</xref>]. Furthermore, although some studies show a close relationship between IL-10 and iNOS levels [<xref ref-type="bibr" rid="B79">79</xref>], no data exists showing a role for IL-10 and eNOS expression. In the present study, we demonstrated a significantly lower IL-10 production by TLN cells in SAL/eNOS mice and OVA/eNOS mice compared to their respective controls. The attenuated IL-10 production in eNOS mice might contribute to the reduced development of asthmatic features in this asthma model.</p><p>Atopic individuals can be recognized by the presence of allergen-specific IgE in their serum and by elevations of the total serum IgE [<xref ref-type="bibr" rid="B6">6</xref>]. Indeed, we found elevated levels of total IgE in serum after ovalbumin challenge, but we could not observe any differences between OVA/WT and OVA/eNOS mice. These results confirm the finding by De Sanctis et al [<xref ref-type="bibr" rid="B50">50</xref>], who observed no difference between IgE levels in several NOS isoform KO mice after challenge with ovalbumin compared to WT mice.</p></sec><sec><title>Conclusion</title><p>We have shown that overexpression of the eNOS gene prevents the development of airway hyperresponsiveness, airway inflammation and the production of Th1 and Th2 cytokines in a mouse model of allergic asthma. Although it has been assumed for many years that iNOS has a primary role in inflammatory diseases like asthma [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B80">80</xref>], recent studies suggest an important role for the cNOS isoforms in controlling asthmatic disease [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B50">50</xref>,<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B81">81</xref>]. Interestingly, eNOS gene polymorphisms have been associated with atopic asthma [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B38">38</xref>], with lower NO concentrations leading to persistent airway inflammation [<xref ref-type="bibr" rid="B37">37</xref>]. The eNOS gene therefore seems a promising new target for new insights and new opportunities for improvements in therapy against asthmatic disease.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>RTB participated in the design and coordination of the study and drafted the manuscript. RDC and RVH generated the eNOS transgenic mice and performed eNOS activity and Western blot analysis. VV, TLM and IVA carried out the all lung experiments. FDC, FN and GF helped to draft the manuscript and participated in the coordination and analysis of the study. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We wish to thank Thijs van Aken for technical assistance.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Folkerts</surname><given-names>G</given-names></name><name><surname>Kloek</surname><given-names>J</given-names></name><name><surname>Muijsers</surname><given-names>RB</given-names></name><name><surname>Nijkamp</surname><given-names>FP</given-names></name></person-group><article-title>Reactive nitrogen and oxygen species in airway inflammation</article-title><source>Eur J Pharmacol</source><year>2001</year><volume>429</volume><fpage>251</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">11698045</pub-id><pub-id pub-id-type="doi">10.1016/S0014-2999(01)01324-3</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>MJ</given-names></name></person-group><article-title>Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>1559</fpage><lpage>1580</lpage><pub-id pub-id-type="pmid">11719293</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Djukanovic</surname><given-names>R</given-names></name><name><surname>Roche</surname><given-names>WR</given-names></name><name><surname>Wilson</surname><given-names>JW</given-names></name><name><surname>Beasley</surname><given-names>CR</given-names></name><name><surname>Twentyman</surname><given-names>OP</given-names></name><name><surname>Howarth</surname><given-names>RH</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name></person-group><article-title>Mucosal inflammation in asthma</article-title><source>Am Rev Respir Dis</source><year>1990</year><volume>142</volume><fpage>434</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">2200318</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname><given-names>JG</given-names></name><name><surname>O'Byrne</surname><given-names>PM</given-names></name><name><surname>Hargreave</surname><given-names>FE</given-names></name></person-group><article-title>Bronchoalveolar lavage does not alter airway responsiveness in asthmatic subjects</article-title><source>Am Rev Respir Dis</source><year>1987</year><volume>135</volume><fpage>554</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">3548505</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>BL</given-names></name><name><surname>Azzawi</surname><given-names>M</given-names></name><name><surname>Jacobson</surname><given-names>M</given-names></name><name><surname>Assoufi</surname><given-names>B</given-names></name><name><surname>Collins</surname><given-names>JV</given-names></name><name><surname>Irani</surname><given-names>AM</given-names></name><name><surname>Schwartz</surname><given-names>LB</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Jeffery</surname><given-names>PK</given-names></name><name><surname>Kay</surname><given-names>AB</given-names></name></person-group><article-title>Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness</article-title><source>J Allergy Clin Immunol</source><year>1991</year><volume>88</volume><fpage>661</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">1918731</pub-id><pub-id pub-id-type="doi">10.1016/0091-6749(91)90160-P</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holgate</surname><given-names>ST</given-names></name></person-group><article-title>The epidemic of allergy and asthma</article-title><source>Nature</source><year>1999</year><volume>402</volume><fpage>B2</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">10586888</pub-id><pub-id pub-id-type="doi">10.1038/35037000</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>AK</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name></person-group><article-title>Functional diversity of helper T lymphocytes</article-title><source>Nature</source><year>1996</year><volume>383</volume><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">8893001</pub-id><pub-id pub-id-type="doi">10.1038/383787a0</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>DS</given-names></name><name><surname>Hamid</surname><given-names>Q</given-names></name><name><surname>Ying</surname><given-names>S</given-names></name><name><surname>Tsicopoulos</surname><given-names>A</given-names></name><name><surname>Barkans</surname><given-names>J</given-names></name><name><surname>Bentley</surname><given-names>AM</given-names></name><name><surname>Corrigan</surname><given-names>C</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Kay</surname><given-names>AB</given-names></name></person-group><article-title>Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma</article-title><source>N Engl J Med</source><year>1992</year><volume>326</volume><fpage>298</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">1530827</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>Ho</surname><given-names>CY</given-names></name><name><surname>Ko</surname><given-names>FW</given-names></name><name><surname>Chan</surname><given-names>CH</given-names></name><name><surname>Ho</surname><given-names>AS</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Lam</surname><given-names>CW</given-names></name></person-group><article-title>Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma</article-title><source>Clin Exp Immunol</source><year>2001</year><volume>125</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">11529906</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2249.2001.01602.x</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>DS</given-names></name><name><surname>Ying</surname><given-names>S</given-names></name><name><surname>Bentley</surname><given-names>AM</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>North</surname><given-names>J</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Kay</surname><given-names>AB</given-names></name><name><surname>Hamid</surname><given-names>Q</given-names></name></person-group><article-title>Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma</article-title><source>J Allergy Clin Immunol</source><year>1993</year><volume>92</volume><fpage>397</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">8360390</pub-id><pub-id pub-id-type="doi">10.1016/0091-6749(93)90118-Y</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cembrzynska-Nowak</surname><given-names>M</given-names></name><name><surname>Szklarz</surname><given-names>E</given-names></name><name><surname>Inglot</surname><given-names>AD</given-names></name><name><surname>Teodorczyk-Injeyan</surname><given-names>JA</given-names></name></person-group><article-title>Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma</article-title><source>Am Rev Respir Dis</source><year>1993</year><volume>147</volume><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">8430950</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corrigan</surname><given-names>CJ</given-names></name><name><surname>Kay</surname><given-names>AB</given-names></name></person-group><article-title>CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status</article-title><source>Am Rev Respir Dis</source><year>1990</year><volume>141</volume><fpage>970</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">1970229</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>L</given-names></name><name><surname>Tepper</surname><given-names>JS</given-names></name><name><surname>Bottomly</surname><given-names>K</given-names></name></person-group><article-title>IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>3813</fpage><lpage>3816</lpage><pub-id pub-id-type="pmid">9780144</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Randolph</surname><given-names>DA</given-names></name><name><surname>Carruthers</surname><given-names>CJ</given-names></name><name><surname>Szabo</surname><given-names>SJ</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Chaplin</surname><given-names>DD</given-names></name></person-group><article-title>Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><fpage>2375</fpage><lpage>2383</lpage><pub-id pub-id-type="pmid">9973518</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takaoka</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Tsuji</surname><given-names>T</given-names></name><name><surname>Jinushi</surname><given-names>T</given-names></name><name><surname>Hoshino</surname><given-names>A</given-names></name><name><surname>Asakura</surname><given-names>Y</given-names></name><name><surname>Mita</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Nakaike</surname><given-names>S</given-names></name><name><surname>Togashi</surname><given-names>Y</given-names></name><name><surname>Koda</surname><given-names>T</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name><name><surname>Nishimura</surname><given-names>T</given-names></name></person-group><article-title>A critical role for mouse cxc chemokine(s) in pulmonary neutrophilia during th type 1-dependent airway inflammation</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><fpage>2349</fpage><lpage>2353</lpage><pub-id pub-id-type="pmid">11490024</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>AP</given-names></name></person-group><article-title>The role of eosinophils and neutrophils in inflammation</article-title><source>Clin Exp Allergy</source><year>2000</year><volume>30 Suppl 1</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">10849470</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2222.2000.00092.x</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Lemanske</surname><given-names>RFJ</given-names></name></person-group><article-title>Asthma</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>350</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">11172168</pub-id><pub-id pub-id-type="doi">10.1056/NEJM200102013440507</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calhoun</surname><given-names>WJ</given-names></name><name><surname>Reed</surname><given-names>HE</given-names></name><name><surname>Moest</surname><given-names>DR</given-names></name><name><surname>Stevens</surname><given-names>CA</given-names></name></person-group><article-title>Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects</article-title><source>Am Rev Respir Dis</source><year>1992</year><volume>145</volume><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">1310575</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ricciardolo</surname><given-names>FL</given-names></name><name><surname>Sterk</surname><given-names>PJ</given-names></name><name><surname>Gaston</surname><given-names>B</given-names></name><name><surname>Folkerts</surname><given-names>G</given-names></name></person-group><article-title>Nitric oxide in health and disease of the respiratory system</article-title><source>Physiol Rev</source><year>2004</year><volume>84</volume><fpage>731</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">15269335</pub-id><pub-id pub-id-type="doi">10.1152/physrev.00034.2003</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hanes</surname><given-names>MA</given-names></name><name><surname>Ahearn</surname><given-names>G</given-names></name><name><surname>McMahon</surname><given-names>TJ</given-names></name><name><surname>Dickfeld</surname><given-names>T</given-names></name><name><surname>Marshall</surname><given-names>HE</given-names></name><name><surname>Que</surname><given-names>LG</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><article-title>Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock</article-title><source>Cell</source><year>2004</year><volume>116</volume><fpage>617</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">14980227</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(04)00131-X</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Que</surname><given-names>LG</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Whitehead</surname><given-names>GS</given-names></name><name><surname>Gavett</surname><given-names>SH</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><article-title>Protection from experimental asthma by an endogenous bronchodilator</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>1618</fpage><lpage>1621</lpage><pub-id pub-id-type="pmid">15919956</pub-id><pub-id pub-id-type="doi">10.1126/science.1108228</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ten Broeke</surname><given-names>R</given-names></name><name><surname>Folkerts</surname><given-names>G</given-names></name><name><surname>Leusink-Muis</surname><given-names>T</given-names></name><name><surname>Van Der Linde</surname><given-names>HJ</given-names></name><name><surname>Villain</surname><given-names>M</given-names></name><name><surname>Manion</surname><given-names>MK</given-names></name><name><surname>De Clerck</surname><given-names>F</given-names></name><name><surname>Blalock</surname><given-names>JE</given-names></name><name><surname>Nijkamp</surname><given-names>FP</given-names></name></person-group><article-title>Calcium sensors as new therapeutic targets for airway hyperresponsiveness and asthma</article-title><source>Faseb J</source><year>2001</year><volume>15</volume><fpage>1831</fpage><lpage>1833</lpage><pub-id pub-id-type="pmid">11481245</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nijkamp</surname><given-names>FP</given-names></name><name><surname>van der Linde</surname><given-names>HJ</given-names></name><name><surname>Folkerts</surname><given-names>G</given-names></name></person-group><article-title>Nitric oxide synthesis inhibitors induce airway hyperresponsiveness in the guinea pig in vivo and in vitro. Role of the epithelium</article-title><source>Am Rev Respir Dis</source><year>1993</year><volume>148</volume><fpage>727</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">8368646</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Folkerts</surname><given-names>G</given-names></name><name><surname>van der Linde</surname><given-names>HJ</given-names></name><name><surname>Nijkamp</surname><given-names>FP</given-names></name></person-group><article-title>Virus-induced airway hyperresponsiveness in guinea pigs is related to a deficiency in nitric oxide</article-title><source>J Clin Invest</source><year>1995</year><volume>95</volume><fpage>26</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">7814624</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Persson</surname><given-names>MG</given-names></name><name><surname>Gustafsson</surname><given-names>LE</given-names></name></person-group><article-title>Allergen-induced airway obstruction in guinea-pigs is associated with changes in nitric oxide levels in exhaled air</article-title><source>Acta Physiol Scand</source><year>1993</year><volume>149</volume><fpage>461</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">8128895</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Boer</surname><given-names>J</given-names></name><name><surname>Meurs</surname><given-names>H</given-names></name><name><surname>Coers</surname><given-names>W</given-names></name><name><surname>Koopal</surname><given-names>M</given-names></name><name><surname>Bottone</surname><given-names>AE</given-names></name><name><surname>Visser</surname><given-names>AC</given-names></name><name><surname>Timens</surname><given-names>W</given-names></name><name><surname>Zaagsma</surname><given-names>J</given-names></name></person-group><article-title>Deficiency of nitric oxide in allergen-induced airway hyperreactivity to contractile agonists after the early asthmatic reaction: an ex vivo study</article-title><source>Br J Pharmacol</source><year>1996</year><volume>119</volume><fpage>1109</fpage><lpage>1116</lpage><pub-id pub-id-type="pmid">8937712</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hogman</surname><given-names>M</given-names></name><name><surname>Frostell</surname><given-names>CG</given-names></name><name><surname>Hedenstrom</surname><given-names>H</given-names></name><name><surname>Hedenstierna</surname><given-names>G</given-names></name></person-group><article-title>Inhalation of nitric oxide modulates adult human bronchial tone</article-title><source>Am Rev Respir Dis</source><year>1993</year><volume>148</volume><fpage>1474</fpage><lpage>1478</lpage><pub-id pub-id-type="pmid">7903023</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>DA</given-names></name><name><surname>McGrath</surname><given-names>JL</given-names></name><name><surname>Orr</surname><given-names>LM</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>O'Connor</surname><given-names>BJ</given-names></name></person-group><article-title>Effect of endogenous nitric oxide inhibition on airway responsiveness to histamine and adenosine-5'-monophosphate in asthma</article-title><source>Thorax</source><year>1998</year><volume>53</volume><fpage>483</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">9713448</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ricciardolo</surname><given-names>FL</given-names></name><name><surname>Geppetti</surname><given-names>P</given-names></name><name><surname>Mistretta</surname><given-names>A</given-names></name><name><surname>Nadel</surname><given-names>JA</given-names></name><name><surname>Sapienza</surname><given-names>MA</given-names></name><name><surname>Bellofiore</surname><given-names>S</given-names></name><name><surname>Di Maria</surname><given-names>GU</given-names></name></person-group><article-title>Randomised double-blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma</article-title><source>Lancet</source><year>1996</year><volume>348</volume><fpage>374</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">8709736</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(96)04450-9</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Redington</surname><given-names>AE</given-names></name><name><surname>Meng</surname><given-names>QH</given-names></name><name><surname>Springall</surname><given-names>DR</given-names></name><name><surname>Evans</surname><given-names>TJ</given-names></name><name><surname>Creminon</surname><given-names>C</given-names></name><name><surname>Maclouf</surname><given-names>J</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Howarth</surname><given-names>PH</given-names></name><name><surname>Polak</surname><given-names>JM</given-names></name></person-group><article-title>Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment</article-title><source>Thorax</source><year>2001</year><volume>56</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">11312402</pub-id><pub-id pub-id-type="doi">10.1136/thorax.56.5.351</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamid</surname><given-names>Q</given-names></name><name><surname>Springall</surname><given-names>DR</given-names></name><name><surname>Riveros-Moreno</surname><given-names>V</given-names></name><name><surname>Chanez</surname><given-names>P</given-names></name><name><surname>Howarth</surname><given-names>P</given-names></name><name><surname>Redington</surname><given-names>A</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Godard</surname><given-names>P</given-names></name><name><surname>Holgate</surname><given-names>S</given-names></name><name><surname>Polak</surname><given-names>JM</given-names></name></person-group><article-title>Induction of nitric oxide synthase in asthma</article-title><source>Lancet</source><year>1993</year><volume>342</volume><fpage>1510</fpage><lpage>1513</lpage><pub-id pub-id-type="pmid">7504773</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(05)80083-2</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Liew</surname><given-names>FY</given-names></name></person-group><article-title>Nitric oxide and asthmatic inflammation</article-title><source>Immunol Today</source><year>1995</year><volume>16</volume><fpage>128</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">7536418</pub-id><pub-id pub-id-type="doi">10.1016/0167-5699(95)80128-6</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansel</surname><given-names>TT</given-names></name><name><surname>Kharitonov</surname><given-names>SA</given-names></name><name><surname>Donnelly</surname><given-names>LE</given-names></name><name><surname>Erin</surname><given-names>EM</given-names></name><name><surname>Currie</surname><given-names>MG</given-names></name><name><surname>Moore</surname><given-names>WM</given-names></name><name><surname>Manning</surname><given-names>PT</given-names></name><name><surname>Recker</surname><given-names>DP</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics</article-title><source>Faseb J</source><year>2003</year><volume>17</volume><fpage>1298</fpage><lpage>1300</lpage><pub-id pub-id-type="pmid">12738811</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Karupiah</surname><given-names>G</given-names></name><name><surname>Hogan</surname><given-names>SP</given-names></name><name><surname>Foster</surname><given-names>PS</given-names></name><name><surname>Ramsay</surname><given-names>AJ</given-names></name></person-group><article-title>Inhibition of allergic airway inflammation in mice lacking nitric oxide synthase 2</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">9886418</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Cheon</surname><given-names>KT</given-names></name><name><surname>Lee</surname><given-names>HB</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Rhee</surname><given-names>YK</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name></person-group><article-title>Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with asthma</article-title><source>Allergy</source><year>2000</year><volume>55</volume><fpage>959</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">11030378</pub-id><pub-id pub-id-type="doi">10.1034/j.1398-9995.2000.00724.x</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsukada</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>K</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Takemoto</surname><given-names>F</given-names></name><name><surname>Hara</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>A</given-names></name><name><surname>Kawaguchi</surname><given-names>Y</given-names></name><name><surname>Hosoya</surname><given-names>T</given-names></name><name><surname>Igari</surname><given-names>J</given-names></name></person-group><article-title>Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans</article-title><source>Biochem Biophys Res Commun</source><year>1998</year><volume>245</volume><fpage>190</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">9535806</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1998.8267</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schuller</surname><given-names>M</given-names></name><name><surname>Stelcl</surname><given-names>M</given-names></name><name><surname>Rybnieek</surname><given-names>O</given-names></name><name><surname>Buekova</surname><given-names>D</given-names></name><name><surname>Izakovieova Holla</surname><given-names>L</given-names></name></person-group><article-title>The ecNOS gene in allergic Czech children</article-title><source>Allergy</source><year>2002</year><volume>57</volume><fpage>368</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">11906374</pub-id><pub-id pub-id-type="doi">10.1034/j.1398-9995.2002.1n3603.x</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yanamandra</surname><given-names>K</given-names></name><name><surname>Boggs</surname><given-names>PB</given-names></name><name><surname>Thurmon</surname><given-names>TF</given-names></name><name><surname>Lewis</surname><given-names>D</given-names></name><name><surname>Bocchini</surname><given-names>JAJ</given-names></name><name><surname>Dhanireddy</surname><given-names>R</given-names></name></person-group><article-title>Novel allele of the endothelial nitric oxide synthase gene polymorphism in Caucasian asthmatics</article-title><source>Biochem Biophys Res Commun</source><year>2005</year><volume>335</volume><fpage>545</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">16081038</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.07.108</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sofowora</surname><given-names>G</given-names></name><name><surname>Dishy</surname><given-names>V</given-names></name><name><surname>Xie</surname><given-names>HG</given-names></name><name><surname>Imamura</surname><given-names>H</given-names></name><name><surname>Nishimi</surname><given-names>Y</given-names></name><name><surname>Morales</surname><given-names>CR</given-names></name><name><surname>Morrow</surname><given-names>JD</given-names></name><name><surname>Kim</surname><given-names>RB</given-names></name><name><surname>Stein</surname><given-names>CM</given-names></name><name><surname>Wood</surname><given-names>AJ</given-names></name></person-group><article-title>In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism</article-title><source>Pharmacogenetics</source><year>2001</year><volume>11</volume><fpage>809</fpage><lpage>814</lpage><pub-id pub-id-type="pmid">11740345</pub-id><pub-id pub-id-type="doi">10.1097/00008571-200112000-00009</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Haperen</surname><given-names>R</given-names></name><name><surname>van Tol</surname><given-names>A</given-names></name><name><surname>Vermeulen</surname><given-names>P</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>van Gent</surname><given-names>T</given-names></name><name><surname>van den Berg</surname><given-names>P</given-names></name><name><surname>Ehnholm</surname><given-names>S</given-names></name><name><surname>Grosveld</surname><given-names>F</given-names></name><name><surname>van der Kamp</surname><given-names>A</given-names></name><name><surname>de Crom</surname><given-names>R</given-names></name></person-group><article-title>Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2000</year><volume>20</volume><fpage>1082</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">10764677</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bradford</surname><given-names>MM</given-names></name></person-group><article-title>A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding</article-title><source>Anal Biochem</source><year>1976</year><volume>72</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">942051</pub-id><pub-id pub-id-type="doi">10.1016/0003-2697(76)90527-3</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamelmann</surname><given-names>E</given-names></name><name><surname>Schwarze</surname><given-names>J</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Oshiba</surname><given-names>A</given-names></name><name><surname>Larsen</surname><given-names>GL</given-names></name><name><surname>Irvin</surname><given-names>CG</given-names></name><name><surname>Gelfand</surname><given-names>EW</given-names></name></person-group><article-title>Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography</article-title><source>Am J Respir Crit Care Med</source><year>1997</year><volume>156</volume><fpage>766</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">9309991</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofstra</surname><given-names>CL</given-names></name><name><surname>Van Ark</surname><given-names>I</given-names></name><name><surname>Hofman</surname><given-names>G</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Nijkamp</surname><given-names>FP</given-names></name><name><surname>Van Oosterhout</surname><given-names>AJ</given-names></name></person-group><article-title>Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>5054</fpage><lpage>5060</lpage><pub-id pub-id-type="pmid">9794443</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>K</given-names></name><name><surname>Ragsdale</surname><given-names>NV</given-names></name><name><surname>Carey</surname><given-names>RM</given-names></name><name><surname>MacDonald</surname><given-names>T</given-names></name><name><surname>Gaston</surname><given-names>B</given-names></name></person-group><article-title>Reductive assays for S-nitrosothiols: implications for measurements in biological systems</article-title><source>Biochem Biophys Res Commun</source><year>1998</year><volume>252</volume><fpage>535</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">9837741</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1998.9688</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braman</surname><given-names>RS</given-names></name><name><surname>Hendrix</surname><given-names>SA</given-names></name></person-group><article-title>Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection</article-title><source>Anal Chem</source><year>1989</year><volume>61</volume><fpage>2715</fpage><lpage>2718</lpage><pub-id pub-id-type="pmid">2619057</pub-id><pub-id pub-id-type="doi">10.1021/ac00199a007</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menon</surname><given-names>NK</given-names></name><name><surname>Patricza</surname><given-names>J</given-names></name><name><surname>Binder</surname><given-names>T</given-names></name><name><surname>Bing</surname><given-names>RJ</given-names></name></person-group><article-title>Reduction of biological effluents in purge and trap micro reaction vessels and detection of endothelium-derived nitric oxide (edno) by chemiluminescence</article-title><source>J Mol Cell Cardiol</source><year>1991</year><volume>23</volume><fpage>389</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">1942075</pub-id><pub-id pub-id-type="doi">10.1016/0022-2828(91)90162-F</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fulton</surname><given-names>D</given-names></name><name><surname>Gratton</surname><given-names>JP</given-names></name><name><surname>McCabe</surname><given-names>TJ</given-names></name><name><surname>Fontana</surname><given-names>J</given-names></name><name><surname>Fujio</surname><given-names>Y</given-names></name><name><surname>Walsh</surname><given-names>K</given-names></name><name><surname>Franke</surname><given-names>TF</given-names></name><name><surname>Papapetropoulos</surname><given-names>A</given-names></name><name><surname>Sessa</surname><given-names>WC</given-names></name></person-group><article-title>Regulation of endothelium-derived nitric oxide production by the protein kinase Akt [In Process Citation]</article-title><source>Nature</source><year>1999</year><volume>399</volume><fpage>597</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">10376602</pub-id><pub-id pub-id-type="doi">10.1038/21218</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Fleming</surname><given-names>I</given-names></name><name><surname>Fisslthaler</surname><given-names>B</given-names></name><name><surname>Hermann</surname><given-names>C</given-names></name><name><surname>Busse</surname><given-names>R</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name></person-group><article-title>Activation of nitric oxide synthase in endothelial cells by Akt- dependent phosphorylation [In Process Citation]</article-title><source>Nature</source><year>1999</year><volume>399</volume><fpage>601</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">10376603</pub-id><pub-id pub-id-type="doi">10.1038/21224</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feletou</surname><given-names>M</given-names></name><name><surname>Lonchampt</surname><given-names>M</given-names></name><name><surname>Coge</surname><given-names>F</given-names></name><name><surname>Galizzi</surname><given-names>JP</given-names></name><name><surname>Bassoullet</surname><given-names>C</given-names></name><name><surname>Merial</surname><given-names>C</given-names></name><name><surname>Robineau</surname><given-names>P</given-names></name><name><surname>Boutin</surname><given-names>JA</given-names></name><name><surname>Huang</surname><given-names>PL</given-names></name><name><surname>Vanhoutte</surname><given-names>PM</given-names></name><name><surname>Canet</surname><given-names>E</given-names></name></person-group><article-title>Regulation of murine airway responsiveness by endothelial nitric oxide synthase</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2001</year><volume>281</volume><fpage>L258</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">11404269</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Sanctis</surname><given-names>GT</given-names></name><name><surname>MacLean</surname><given-names>JA</given-names></name><name><surname>Hamada</surname><given-names>K</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>JA</given-names></name><name><surname>Jiao</surname><given-names>A</given-names></name><name><surname>Yandava</surname><given-names>CN</given-names></name><name><surname>Kobzik</surname><given-names>L</given-names></name><name><surname>Wolyniec</surname><given-names>WW</given-names></name><name><surname>Fabian</surname><given-names>AJ</given-names></name><name><surname>Venugopal</surname><given-names>CS</given-names></name><name><surname>Grasemann</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>PL</given-names></name><name><surname>Drazen</surname><given-names>JM</given-names></name></person-group><article-title>Contribution of nitric oxide synthases 1, 2, and 3 to airway hyperresponsiveness and inflammation in a murine model of asthma</article-title><source>J Exp Med</source><year>1999</year><volume>189</volume><fpage>1621</fpage><lpage>1630</lpage><pub-id pub-id-type="pmid">10330441</pub-id><pub-id pub-id-type="doi">10.1084/jem.189.10.1621</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feder</surname><given-names>LS</given-names></name><name><surname>Stelts</surname><given-names>D</given-names></name><name><surname>Chapman</surname><given-names>RW</given-names></name><name><surname>Manfra</surname><given-names>D</given-names></name><name><surname>Crawley</surname><given-names>Y</given-names></name><name><surname>Jones</surname><given-names>H</given-names></name><name><surname>Minnicozzi</surname><given-names>M</given-names></name><name><surname>Fernandez</surname><given-names>X</given-names></name><name><surname>Paster</surname><given-names>T</given-names></name><name><surname>Egan</surname><given-names>RW</given-names></name><name><surname>Kreutner</surname><given-names>W</given-names></name><name><surname>Kung</surname><given-names>TT</given-names></name></person-group><article-title>Role of nitric oxide on eosinophilic lung inflammation in allergic mice</article-title><source>Am J Respir Cell Mol Biol</source><year>1997</year><volume>17</volume><fpage>436</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">9376118</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moncada</surname><given-names>S</given-names></name><name><surname>Palmer</surname><given-names>RM</given-names></name><name><surname>Higgs</surname><given-names>EA</given-names></name></person-group><article-title>Nitric oxide: physiology, pathophysiology, and pharmacology</article-title><source>Pharmacol Rev</source><year>1991</year><volume>43</volume><fpage>109</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">1852778</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaston</surname><given-names>B</given-names></name><name><surname>Sears</surname><given-names>S</given-names></name><name><surname>Woods</surname><given-names>J</given-names></name><name><surname>Hunt</surname><given-names>J</given-names></name><name><surname>Ponaman</surname><given-names>M</given-names></name><name><surname>McMahon</surname><given-names>T</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><article-title>Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>1317</fpage><lpage>1319</lpage><pub-id pub-id-type="pmid">9643794</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(97)07485-0</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reynaert</surname><given-names>NL</given-names></name><name><surname>Ckless</surname><given-names>K</given-names></name><name><surname>Korn</surname><given-names>SH</given-names></name><name><surname>Vos</surname><given-names>N</given-names></name><name><surname>Guala</surname><given-names>AS</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>van der Vliet</surname><given-names>A</given-names></name><name><surname>Janssen-Heininger</surname><given-names>YM</given-names></name></person-group><article-title>Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>8945</fpage><lpage>8950</lpage><pub-id pub-id-type="pmid">15184672</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0400588101</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Busse</surname><given-names>WW</given-names></name></person-group><article-title>Inflammation in asthma: the cornerstone of the disease and target of therapy</article-title><source>J Allergy Clin Immunol</source><year>1998</year><volume>102</volume><fpage>S17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">9798720</pub-id><pub-id pub-id-type="doi">10.1016/S0091-6749(98)70002-8</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>HH</given-names></name><name><surname>Medeiros</surname><given-names>MV</given-names></name><name><surname>Lima</surname><given-names>CS</given-names></name><name><surname>Flores</surname><given-names>CA</given-names></name><name><surname>Sannomiya</surname><given-names>P</given-names></name><name><surname>Autunes</surname><given-names>E</given-names></name><name><surname>De Nucci</surname><given-names>G</given-names></name></person-group><article-title>Inhibition of eosinophil chemotaxis by chronic blockade of nitric oxide biosynthesis</article-title><source>Eur J Pharmacol</source><year>1996</year><volume>310</volume><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">8884218</pub-id><pub-id pub-id-type="doi">10.1016/0014-2999(96)00379-2</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stirling</surname><given-names>RG</given-names></name><name><surname>Chung</surname><given-names>KF</given-names></name></person-group><article-title>Future treatments of allergic diseases and asthma</article-title><source>Br Med Bull</source><year>2000</year><volume>56</volume><fpage>1037</fpage><lpage>1053</lpage><pub-id pub-id-type="pmid">11359636</pub-id><pub-id pub-id-type="doi">10.1258/0007142001903526</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karras</surname><given-names>JG</given-names></name><name><surname>McGraw</surname><given-names>K</given-names></name><name><surname>McKay</surname><given-names>RA</given-names></name><name><surname>Cooper</surname><given-names>SR</given-names></name><name><surname>Lerner</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Walker</surname><given-names>C</given-names></name><name><surname>Dean</surname><given-names>NM</given-names></name><name><surname>Monia</surname><given-names>BP</given-names></name></person-group><article-title>Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma</article-title><source>J Immunol</source><year>2000</year><volume>164</volume><fpage>5409</fpage><lpage>5415</lpage><pub-id pub-id-type="pmid">10799906</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hessel</surname><given-names>EM</given-names></name><name><surname>Van Oosterhout</surname><given-names>AJ</given-names></name><name><surname>Van Ark</surname><given-names>I</given-names></name><name><surname>Van Esch</surname><given-names>B</given-names></name><name><surname>Hofman</surname><given-names>G</given-names></name><name><surname>Van Loveren</surname><given-names>H</given-names></name><name><surname>Savelkoul</surname><given-names>HF</given-names></name><name><surname>Nijkamp</surname><given-names>FP</given-names></name></person-group><article-title>Development of airway hyperresponsiveness is dependent on interferon-gamma and independent of eosinophil infiltration</article-title><source>Am J Respir Cell Mol Biol</source><year>1997</year><volume>16</volume><fpage>325</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">9070618</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>PS</given-names></name><name><surname>Hogan</surname><given-names>SP</given-names></name><name><surname>Ramsay</surname><given-names>AJ</given-names></name><name><surname>Matthaei</surname><given-names>KI</given-names></name><name><surname>Young</surname><given-names>IG</given-names></name></person-group><article-title>Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model</article-title><source>J Exp Med</source><year>1996</year><volume>183</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">8551223</pub-id><pub-id pub-id-type="doi">10.1084/jem.183.1.195</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denburg</surname><given-names>JA</given-names></name></person-group><article-title>Bone marrow in atopy and asthma: hematopoietic mechanisms in allergic inflammation</article-title><source>Immunol Today</source><year>1999</year><volume>20</volume><fpage>111</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">10203700</pub-id><pub-id pub-id-type="doi">10.1016/S0167-5699(98)01423-6</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kubes</surname><given-names>P</given-names></name><name><surname>Kurose</surname><given-names>I</given-names></name><name><surname>Granger</surname><given-names>DN</given-names></name></person-group><article-title>NO donors prevent integrin-induced leukocyte adhesion but not P-selectin-dependent rolling in postischemic venules</article-title><source>Am J Physiol</source><year>1994</year><volume>267</volume><fpage>H931</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7522408</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albina</surname><given-names>JE</given-names></name><name><surname>Abate</surname><given-names>JA</given-names></name><name><surname>Henry</surname><given-names>WLJ</given-names></name></person-group><article-title>Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. Role of IFN-gamma in the induction of the nitric oxide-synthesizing pathway</article-title><source>J Immunol</source><year>1991</year><volume>147</volume><fpage>144</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">1904899</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Veen</surname><given-names>RC</given-names></name></person-group><article-title>Nitric oxide and T helper cell immunity</article-title><source>Int Immunopharmacol</source><year>2001</year><volume>1</volume><fpage>1491</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">11515814</pub-id><pub-id pub-id-type="doi">10.1016/S1567-5769(01)00093-5</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benhar</surname><given-names>M</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><article-title>A central role for S-nitrosylation in apoptosis</article-title><source>Nat Cell Biol</source><year>2005</year><volume>7</volume><fpage>645</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">15990893</pub-id><pub-id pub-id-type="doi">10.1038/ncb0705-645</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>MR</given-names></name><name><surname>Agrawal</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>SF</given-names></name><name><surname>Cascio</surname><given-names>MB</given-names></name><name><surname>Fujimuro</surname><given-names>M</given-names></name><name><surname>Ozeki</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Cheah</surname><given-names>JH</given-names></name><name><surname>Tankou</surname><given-names>SK</given-names></name><name><surname>Hester</surname><given-names>LD</given-names></name><name><surname>Ferris</surname><given-names>CD</given-names></name><name><surname>Hayward</surname><given-names>SD</given-names></name><name><surname>Snyder</surname><given-names>SH</given-names></name><name><surname>Sawa</surname><given-names>A</given-names></name></person-group><article-title>S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding</article-title><source>Nat Cell Biol</source><year>2005</year><volume>7</volume><fpage>665</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">15951807</pub-id><pub-id pub-id-type="doi">10.1038/ncb1268</pub-id></citation></ref><ref id="B67"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Adelroth</surname><given-names>EAC</given-names></name><name><surname>O'Byrne</surname><given-names>PM</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Busse W and Holgate S</surname></name></person-group><article-title>Inflammatory mechanisms in airway hyperresponsiveness</article-title><source>Asthma and rhinitis</source><year>2000</year><volume>2</volume><publisher-name>London, Blackwell Science</publisher-name><fpage>1273</fpage><lpage>1281</lpage></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>AB</given-names></name></person-group><article-title>Allergy and allergic diseases. First of two parts</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>30</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">11136958</pub-id><pub-id pub-id-type="doi">10.1056/NEJM200101043440106</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>C</given-names></name><name><surname>Bode</surname><given-names>E</given-names></name><name><surname>Boer</surname><given-names>L</given-names></name><name><surname>Hansel</surname><given-names>TT</given-names></name><name><surname>Blaser</surname><given-names>K</given-names></name><name><surname>Virchow</surname><given-names>JCJ</given-names></name></person-group><article-title>Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage</article-title><source>Am Rev Respir Dis</source><year>1992</year><volume>146</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">1626792</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>G</given-names></name><name><surname>Berry</surname><given-names>G</given-names></name><name><surname>DeKruyff</surname><given-names>RH</given-names></name><name><surname>Umetsu</surname><given-names>DT</given-names></name></person-group><article-title>Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation</article-title><source>J Clin Invest</source><year>1999</year><volume>103</volume><fpage>175</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">9916129</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calhoun</surname><given-names>WJ</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Stevens</surname><given-names>CA</given-names></name><name><surname>Jarjour</surname><given-names>NN</given-names></name><name><surname>Busse</surname><given-names>WW</given-names></name></person-group><article-title>Increased interferon-y and tumor necrosis factor-alpha in bronchoalveolar lavage (BAL) fluid after antigen challenge in allergic subjects</article-title><source>Am Rev Respir Dis</source><year>1992</year><volume>145</volume><fpage>abstract</fpage></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leckie</surname><given-names>MJ</given-names></name><name><surname>ten Brinke</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>J</given-names></name><name><surname>Diamant</surname><given-names>Z</given-names></name><name><surname>O'Connor</surname><given-names>BJ</given-names></name><name><surname>Walls</surname><given-names>CM</given-names></name><name><surname>Mathur</surname><given-names>AK</given-names></name><name><surname>Cowley</surname><given-names>HC</given-names></name><name><surname>Chung</surname><given-names>KF</given-names></name><name><surname>Djukanovic</surname><given-names>R</given-names></name><name><surname>Hansel</surname><given-names>TT</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Sterk</surname><given-names>PJ</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response</article-title><source>Lancet</source><year>2000</year><volume>356</volume><fpage>2144</fpage><lpage>2148</lpage><pub-id pub-id-type="pmid">11191542</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)03496-6</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roozendaal</surname><given-names>R</given-names></name><name><surname>Vellenga</surname><given-names>E</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>De Monchy</surname><given-names>JG</given-names></name><name><surname>Kauffman</surname><given-names>HF</given-names></name></person-group><article-title>Nitric oxide selectively decreases interferon-gamma expression by activated human T lymphocytes via a cGMP-independent mechanism</article-title><source>Immunology</source><year>1999</year><volume>98</volume><fpage>393</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">10583599</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2567.1999.00895.x</pub-id></citation></ref><ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor-Robinson</surname><given-names>AW</given-names></name><name><surname>Liew</surname><given-names>FY</given-names></name><name><surname>Severn</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>McSorley</surname><given-names>SJ</given-names></name><name><surname>Garside</surname><given-names>P</given-names></name><name><surname>Padron</surname><given-names>J</given-names></name><name><surname>Phillips</surname><given-names>RS</given-names></name></person-group><article-title>Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells</article-title><source>Eur J Immunol</source><year>1994</year><volume>24</volume><fpage>980</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">8149966</pub-id></citation></ref><ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>H</given-names></name><name><surname>Jung</surname><given-names>T</given-names></name><name><surname>Tsikas</surname><given-names>D</given-names></name><name><surname>Stichtenoth</surname><given-names>DO</given-names></name><name><surname>Frolich</surname><given-names>JC</given-names></name><name><surname>Neumann</surname><given-names>C</given-names></name></person-group><article-title>Nitric oxide inhibits the secretion of T-helper 1- and T-helper 2-associated cytokines in activated human T cells</article-title><source>Immunology</source><year>1997</year><volume>90</volume><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">9135548</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2567.1997.00161.x</pub-id></citation></ref><ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname><given-names>H</given-names></name><name><surname>Bogdan</surname><given-names>C</given-names></name></person-group><article-title>NO as a signaling molecule: effects on kinases</article-title><source>International Immunopharmacology</source><year>2001</year><volume>1</volume><fpage>1443</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">11515810</pub-id><pub-id pub-id-type="doi">10.1016/S1567-5769(01)00089-3</pub-id></citation></ref><ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>DS</given-names></name><name><surname>Tsicopoulos</surname><given-names>A</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Durham</surname><given-names>S</given-names></name><name><surname>Kay</surname><given-names>AB</given-names></name><name><surname>Hamid</surname><given-names>Q</given-names></name></person-group><article-title>Increased interleukin-10 messenger RNA expression in atopic allergy and asthma</article-title><source>Am J Respir Cell Mol Biol</source><year>1996</year><volume>14</volume><fpage>113</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">8630259</pub-id></citation></ref><ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borish</surname><given-names>L</given-names></name><name><surname>Aarons</surname><given-names>A</given-names></name><name><surname>Rumbyrt</surname><given-names>J</given-names></name><name><surname>Cvietusa</surname><given-names>P</given-names></name><name><surname>Negri</surname><given-names>J</given-names></name><name><surname>Wenzel</surname><given-names>S</given-names></name></person-group><article-title>Interleukin-10 regulation in normal subjects and patients with asthma</article-title><source>J Allergy Clin Immunol</source><year>1996</year><volume>97</volume><fpage>1288</fpage><lpage>1296</lpage><pub-id pub-id-type="pmid">8648025</pub-id><pub-id pub-id-type="doi">10.1016/S0091-6749(96)70197-5</pub-id></citation></ref><ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ameredes</surname><given-names>BT</given-names></name><name><surname>Zamora</surname><given-names>R</given-names></name><name><surname>Gibson</surname><given-names>KF</given-names></name><name><surname>Billiar</surname><given-names>TR</given-names></name><name><surname>Dixon-McCarthy</surname><given-names>B</given-names></name><name><surname>Watkins</surname><given-names>S</given-names></name><name><surname>Calhoun</surname><given-names>WJ</given-names></name></person-group><article-title>Increased nitric oxide production by airway cells of sensitized and challenged IL-10 knockout mice</article-title><source>J Leukoc Biol</source><year>2001</year><volume>70</volume><fpage>730</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">11698492</pub-id></citation></ref><ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trifilieff</surname><given-names>A</given-names></name><name><surname>Fujitani</surname><given-names>Y</given-names></name><name><surname>Mentz</surname><given-names>F</given-names></name><name><surname>Dugas</surname><given-names>B</given-names></name><name><surname>Fuentes</surname><given-names>M</given-names></name><name><surname>Bertrand</surname><given-names>C</given-names></name></person-group><article-title>Inducible nitric oxide synthase inhibitors suppress airway inflammation in mice through down-regulation of chemokine expression</article-title><source>J Immunol</source><year>2000</year><volume>165</volume><fpage>1526</fpage><lpage>1533</lpage><pub-id pub-id-type="pmid">10903760</pub-id></citation></ref><ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samb</surname><given-names>A</given-names></name><name><surname>Pretolani</surname><given-names>M</given-names></name><name><surname>Dinh-Xuan</surname><given-names>AT</given-names></name><name><surname>Ouksel</surname><given-names>H</given-names></name><name><surname>Callebert</surname><given-names>J</given-names></name><name><surname>Lisdero</surname><given-names>C</given-names></name><name><surname>Aubier</surname><given-names>M</given-names></name><name><surname>Boczkowski</surname><given-names>J</given-names></name></person-group><article-title>Decreased pulmonary and tracheal smooth muscle expression and activity of type 1 nitric oxide synthase (nNOS) after ovalbumin immunization and multiple aerosol challenge in guinea pigs</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">11435253</pub-id></citation></ref></ref-list></back></article> 